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Objective: The aim of this study was to investigate the in vitro and in vivo biological responses to nanostructured carbonated hydroxyapatite/calcium alginate (CHA) 
microspheres used for alveolar bone repair, compared to sintered hydroxyapatite (HA). 
Material and Methods: The maxillary central incisors of 45 Wistar rats were extracted, 
and the dental socNets were ¿lled with HA, CHA, and blood clot (control group) (n 5/
period/group). After 7, 21 and 42 days, the samples of bone with the biomaterials were 
obtained for histological and histomorphometric analysis, and the plasma levels of RANKL 
and OPG were determined via immunoassay. Statistical analysis was performed by Two-
Way ANOVA with post-hoc TuNey test at 5 level of signi¿cance. Results: The CHA and 
HA microspheres were cytocompatible with both human and murine cells on an in vitro 
assay. Histological analysis showed the time-dependent increase of newly formed bone in 
control group characterized by an intense osteoblast activity. In HA and CHA groups, the 
presence of a slight granulation reaction around the spheres was observed after seven 
days, which was reduced by the 42nd day. A considerable amount of newly formed bone 
was observed surrounding the CHA spheres and the biomaterials particles at 42-day time 
point compared with HA. Histomorphometric analysis showed a signi¿cant increase of 
newly formed bone in CHA group compared with HA after 21 and 42 days from surgery, 
moreover, CHA showed almost 2-fold greater biosorption than HA at 42 days (two-way 
ANOVA, p<0.05) indicating greater biosorption. An increase in the RANKL/OPG ratio was 
observed in the CHA group on the 7th day. Conclusion: CHA spheres were osteoconductive 
and presented earlier biosorption, inducing early increases in the levels of proteins involved 
in resorption. 
Keywords: Hydroxyapatite. Bone repair. Biocompatibility testing. RANKL/OPG. Rats.
INTRODUCTION
The application of procedures for bone 
regeneration is becoming a daily practice in 
orthopedic and maxillofacial surgery, motivated 
by the wide acceptance of dental implants as an 
option for oral rehabilitation. For instance, dento-
alveolar trauma usually demands reconstruction 
of the alveolar crest before an implant can be put 
in place13. Several studies have demonstrated the 
potential for the use of autogenous bone grafts 
for bone regeneration due to the bone-forming 
cells potentially harbored in such grafts and their 
ability to release substances that induce bone 
formation (osteogenesis) as well as to serve as a 
scaffold for bone formation (osteoconductivity)11,26. 
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However, difficulties in obtaining autogenous 
bone grafts and limitations, such as postoperative 
discomfort in patients, donor site morbidity, and 
the limited availability of graft materials, as well 
as ethical issues and the possibility of disease 
transmission from allogeneic or xenogeneic grafts, 
have motivated researchers to develop synthetic or 
alloplastic materials1,16,17,22. In this context, calcium 
phosphates present interesting features related 
to bone-targeting applications such as excellent 
bioactivity, the ability to bond directly to bone, and 
osteoconductivity. In addition, calcium phosphates 
can be resorbed, showing solubility rates that are 
dependent on their composition and microstructural 
features10.
Hydroxyapatite (HA), Ca10(PO4)6(OH)2, is the 
main mineral component of bone and teeth, and 
has been widely applied as a biomaterial due to 
its well-known bioactivity and osteoconductivity, 
even though HA ceramics are poorly degradable 
under physiological conditions12. Nevertheless, its 
structure allows isomorphic cationic and anionic 
substitutions to be easily introduced20, which 
can alter the crystallinity, morphology, lattice 
parameters, crystal size, stability, bioactivity, 
biocompatibility, and osteoconductivity of HA4, 
offering alternatives for the development of 
improved materials. For instance, changes in the 
chemical composition of HA induced through partial 
substitution of the phosphate group (PO4) with a 
carbonate group (CO3) lead to the formation of a 
B type carbonated hydroxyapatite (CHA). CHA has 
been proposed as an alternative material for bone 
regeneration not only due to its similarity to the 
mineral phase of calci¿ed tissue, but mainly because 
this material may overcome limitations related to 
crystallinity and low solubility, and therefore extend 
the therapeutic capacity of HA12,28. Moreover, the 
alginate was included in the material, since it is a 
biocompatible and soluble biopolymer, commonly 
used to allow the formation of hydroxyapatite 
microspheres; it also modulates the degradation 
rate of the biomaterial28.
With the progress of nanotechnology, another 
important development in materials science has 
been the synthesis of HA-based ceramics at the 
nanometric level, producing HA nanoparticles, 
blocks, coatings, and nanostructured materials2. 
The rationale for the use of nanostructured CHA 
(produced from particles smaller than 100 nm) 
is based on the fact that natural bone formation 
involves particles of a similar nanometric size18,27. 
Nanoparticles are also expected to exhibit improved 
bioactive properties28. Recent studies have 
shown that nanostructured calcium phosphates 
display better selective protein adsorption ability 
in vivo, and can also regulate the cascade of 
expression of speci¿c intracellular genes and cell 
behaviors, thus inducing the regeneration of speci¿c 
tissues23. These materials can be synthesized 
through diverse methodologies, including the 
precipitation of nanometric particles at relatively 
low processing temperatures (below 10°C) via a 
procedure that may even produce nanostructured 
carbonated hydroxyapatite28. However, there 
are few evidences regarding the bioactivity 
of low crystalline nanostructured carbonated 
hydroxyapatite and the impact on the outcome 
of alveolar bone repair during oral rehabilitation 
procedures. Therefore, the aim of the present study 
was to evaluate the biocompatibility of spheres 
of nanostructured carbonated hydroxyapatite/
calcium alginate, employing stoichiometric sintered 
hydroxyapatite spheres as a reference and 
comparing their effectiveness in alveolar bone 
repair, while determining their correlation with two 
relevant plasma biochemical markers of the bone 
remodeling/resorption process, namely RANKL 
(Receptor Activating Factor Nuclear Kappa-ǃ) and 
OPG (Osteoprotegerin).
MATERIAL AND METHODS
Material
Carbonated hydroxyapatite powder was 
synthesized from aqueous solutions of extra-
pure calcium nitrate tetra-hydrate, dihydrogen 
ammonium phosphate, and ammonium carbonate 
(Merck, Taquara, Rio de Janeiro, Brazil). The 
reagents were mixed and maintained at 5°C 
for 2 h at pH=13 in the presence of KOH with 
a stoichiometry of 1.6<Ca/P<2.0. The X-ray 
diffraction pattern of the CHA powder (Figure 1) 
presented broad peaks due to the nanostructured 
and poorly crystalline nanostructure compared 
Figure 1- X-Ray Diffraction pattern (XRD) of the 
carbonated hydroxyapatite (CHA) powder. Observe broad 
peaks due to the nanostructured and poorly crystalline 
character of the CHA
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with HA. The carbonated hydroxyapatite and 
hydroxyapatite powders (<74 μm) were mixed in 
a sodium alginate solution (Sigma Aldrich®/Fluka 
Biochemika®, St. Louis, Missouri, USA), 1% wt 
with light agitation of calcium chloride (CaCl2, 0.15 
M) at room temperature (approximately 20°C) to 
obtain microspheres with different diameters as a 
result of the ionic interchange between the sodium 
alginate and calcium chloride; it also modulates 
the degradation rates of the biomaterial. The 
microspheres were removed from the solution, 
sieved (425< 425<<550 ǋm), washed in Milli4 
water (MilliQ®, Millipore Corporation, Billerica, 
Massachusetts, USA) and dried in an oven at 70°C 
for 24 h (Figure 2). The HA samples were sintered 
at 1000°C for 27 hours to obtain a crystalline 
biomaterial, and the CHA spheres were not 
thermally treated. The samples were synthesized 
and characterized at the Brazilian Center of Physics 
Research. The materials were sterilized by gamma 
radiation (25 kGrays), according to ISO 11137 
(Sterilization of health care-products-Radiation) 
at the Nuclear Instrumentation Laboratory, COPPE, 
Rio de Janeiro Federal University (the biomaterial 
synthesis is under patent process).
In vitro analysis – multiparametric 
cytotoxicity assay
Prior to animal testing, the cytocompatibility of 
the materials employed in this study was evaluated 
in accordance with the recommendations contained 
in ISO 7405:2008 regarding the assessment of 
dental materials. Extracts were prepared via the 
immersion of 200 mg of biomaterial spheres in 10 
mL of culture medium (DMEM, Dulbelcco, St. Louis, 
Missouri, USA) by 24 hours at 37°C. Subsequently, 
these extracts were added to subcultures of either 
(i) a murine pre-osteoblast cell line (MC3T3-E1) 
or (ii) primary human osteoblasts (Hob) obtained 
from the collection at Clinical Research Unit-Antonio 
Pedro University Hospital. The cells were seeded 
into 96-well culture plates at a density of 104 cells/
well, and incubated in the presence of the extracts 
for 24 hours at 37°C under 5% CO2. At the end of 
incubation period, the cells were washed with PBS, 
and viability tests were performed.
Cell viability was assessed using a multiparametric 
method8 that allows various parameters related to 
survival to be analyzed in the same exposed cells. 
These parameters included mitochondrial activity 
(XTT Test), membrane integrity (Neutral Red Uptake 
Assay, NR) and cell densities (Crystal Violet Dye 
Exclusion assay, CVDE). For these tests, commercial 
kits were used (In Cytotox, Xenometrix, Allschwil, 
Arlesheim, Switzerland).
In vivo analysis of biocompatibility
Experimental groups
All procedures were carried out in accordance 
with conventional guidelines in the Guide for 
the Care and Use of Laboratory Animals (US 
National Institutes of Health 85-23, revised 
1996). The local Institutional Animal Care and 
Use Committee of Fluminense Federal University, 
Figure 2- Scanning Electron Microscopy (SEM) micrographs. A: Carbonated hydroxyapatite (CHA) spheres; B: CHA 
spheres surface, both without thermal treatment; C: Hydroxyapatite (HA) spheres, and D: HA spheres surface. A and C: 
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Niteroi, Brazil (protocol number 194/10) approved 
all experimental protocols.
Three-month-old male Wistar rats weighing 
approximately 250 g were maintained under 
standard conditions with free access to food and 
water. A total of 45 animals were divided into 3 
groups and examined after different experimental 
periods (7, 21 or 42 days after surgery). Fifteen 
animals were distributed into three experimental 
groups, with 5 of the rats surgically treated with 
CHA (CHA group), 5 treated with the reference 
material (HA group), and 5 to control group (non-
grafted alveolar sockets).
Surgical procedures
All animals were anesthetized with ketamine (20 
mg/kg) (Virbac, Jurubatuba, SP, Brazil) and xylazine 
(1 mg/Kg) (FortDodge, São Cristovão, RJ, Brazil). 
Subsequently, syndesmotomy of periodontal tissue 
was performed using a syndesmotome (DuÀex®, Rio 
de Janeiro, Rio de Janeiro, Brazil), and the upper-
right incisor was extracted with a clinical probe 
adapted to this tooth (Figure 3A). The dental sockets 
were ¿lled with nanostructured hydroxyapatite 
carbonated (CHA group), hydroxyapatite (HA 
group), or blood clot (control group), and sutured 
with Vicryl 4-0 (Johnson & Johnson Medical Ltd., 
Blue Ash, Ohio, United States) (Figure 3B). The 
rats were anesthetized and killed with the same 
anesthetic agents used for surgical implantation at 
the end of the experimental period, either 7, 21 or 
42 days after surgery, and samples containing the 
biomaterials were removed.
Descriptive histological analysis
Noncalcified samples were histologically 
processed via embedding in paraf¿n, cut into 5 
ǋm-thick sections and stained with Hematoxylin 
and Eosin (HE) for light microscopy assessment 
(Olympus BX43, Tokyo, Kanto, Japan). The 
reaction of the cells to the biomaterials was 
observed, focusing on the intensity and nature of 
the inÀammatory response and the presence of 
necrosis, ¿brous connective tissue and neoformed 
bone in direct contact with the graft.
Histomorphometric analysis
For histomorphometric analysis, a light 
microscope (Olympus BX43, Tokyo, Kanto, 
Japan) with 10x of magni¿cation was used. The 
microscope was connected to a computer and each 
HE-stained histological slice corresponding to the 
alveolar region was captured by scanning by Image 
acquisition software (Cellsens® 1.9 Digital, Tokyo, 
Kanto, Japan). One expert observer analysed ten 
non-consecutive images of each section. With the 
Image-Pro Plus® 6.0 (Media Cybernetics, Silver 
Spring, Maryland, USA), a grid of 200 points 
were superimposed on captured ¿eld, permitting 
the determination of newly formed bone and the 
residual biomaterial. The bone volume density (BV/
TV%) was calculated by bone volume over total 
volume, indicating the fraction of volume of interest 
that was occupied by bone. For biomaterial volume 
density (BiomatV/TV%), the same calculation 
method was applied. The areas were expressed in 
percentage.
Determination of plasma RANKL and OPG 
levels
Blood samples (5 mL) were collected from each 
animal via cardiac puncture following intraperitoneal 
anesthesia with ketamine (75 mg/kg) and xylazine 
(5 mg/kg). The samples were subsequently 
centrifuged at 1,700 rpm for 10 min, without 
hemolysis, and the plasma was collected and stored 
in a freezer at -80°C for posterior analysis. The total 
plasma levels of RANKL and OPG were assessed 
in immunoassays based on xMAP technology with 
a Luminex S200 Multiplex Flow Luminometer 
(Luminexcorp, Austin, Texas, USA), employing 
commercial kits (Rat Bone Panel 1 Milliplex MAP 
kit, Millipore, Billerica, Massachusetts, USA). The 
results were analyzed using Xponent v. 3.0 software 
Figure 3- Surgical procedures for biomaterials implantation: A: The maxillary right incisor was extracted, and B: The socket 
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A B
Cytocompatibility and biocompatibility of nanostructured carbonated hydroxyapatite spheres for bone repair
2015;23(6):599-608
J Appl Oral Sci. 603
(Luminexcorp, Austin, Texas USA).
Statistical analysis
The mean values and standard deviations 
obtained in each cytotoxicity assay (n=3 trials in 
quintuplicate) were tested for normality according 
to D’Agostino and Pearson’s omnibus. Upon 
verification of a normal distribution, two-way 
ANOVA was conducted together with Tukey’s post-
hoc test. The signi¿cance level was set at p=0.05. 
Also, after the normality test, a quantitative 
description with means and con¿dence interval (CI) 
of BV/TV% and BiomatV/TV% was performed. The 
analysis of variance of two-way ANOVA and Tukey’s 
post-hoc test was applied, and two assignable 
sources of variation - groups and periods - were 
evaluated. The signi¿cance level was set at p=0.05. 
Both in vitro and in vivo analyzes were performed 
using Prism Graph Pad 6.3 software (Inc. La Jolla, 
California, USA).
RESULTS
In vitro evaluation of biocompatibility
The cytotoxicity assays, performed using murine 
pre-osteoblasts (MC3T3-E1), showed that both 
the CHA and HA groups were cytocompatible, 
with more than 75% cell survival observed when 
compared to the experimental control group (cells 
exposed to culture medium), as recommended by 
international standards (ISO 7405:2008). Moreover, 
the results observed in the CHA group were similar 
to those of the experimental and negative control 
(polystyrene) groups for the evaluated parameters. 
These ¿ndings were obtained in both murine (Figure 
4) and human primary bone cells (Figure 5). It could 
also be observed that both the positive and negative 
controls behaved as expected, with polystyrene 
being highly cytocompatible, while latex extracts 
dramatically reduced cell viability in all assays. 
Therefore, the materials were considered to be 
suitable for subsequent in vivo tests.
Histological analyses
Morphological analysis was performed at light 
microscope after hematoxylin-eosin staining. 
The Figures 6, 7 and 8 contain representative 
photomicrographs of alveolar socket from each 
implanted biomaterials and control group at 
magni¿cation of 4 and 40X.
In seven days, the control group showed few 
trabeculae of newly formed bone with osteoblasts 
pavement on periphery, interspersed by connective 
tissue containing serum hemorrhagic exudate 
(Figures 6A and 6B). Both biomaterial groups 
presented the dental socket ¿lled by biomaterial 
spheres (Figures 6C and 6E) permeated by 
connective tissue characterized by granulation 
reaction. In HA group, focal areas of scanty 
neutrophilic in¿ltrate surrounding the spheres were 
observed (Figure 6D). In CHA group, an initial 
osteoid deposition surrounding the spheres was 
found (Figure 6F).
At 21-day time point, the control group 
presented more trabeculae of newly formed bone 
Figure 4- Multiparametric cytotoxicity assay with murine 
MC3T3-E1 cells. Results showed as percentage of 
???????? ?????? ?????????? ????????? ?????????? ?? ?? ???? ????
other groups (p<0.05)
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than 7-day time point, interspersed by connective 
tissue and hemorrhagic exudate. The newly formed 
bone was surrounded by osteoblasts line (Figures 
7A and 7B). The spheres of HA group were not 
dispersed (Figure 7C) as in the ¿rst period yet. 
In the CHA group, the same spheres presented 
a smaller diameter than at day 7 (Figure 7E), 
and displayed some areas of biomaterial particles 
suggesting a biosorption. Islands of newly formed 
bone surrounding the biomaterials spheres were 
observed at high magni¿cation at both groups 
(Figures 7D and 7F).
After 42 days, the alveolar socket of control 
group was almost ¿lled by newly formed bone 
interspersed by connective tissue and remnant 
hemorrhagic exudate (Figures 8A). At high 
magni¿cation, there was observed the trabeculae 
periphery surrounded by a large osteoblasts 
pavement (Figures 8B). Both groups of biomaterials 
presented a reduction of biomaterial amount 
compared with previous periods (Figures 8C and 
8E). The HA group showed regions of newly formed 
bone surrounding the spheres (Figures 8D). A 
reduction of the amount of discernible CHA spheres 
could be observed between 7 and 42 days (Figures 
6E and 8E). A considerable amount of newly formed 
bone was observed surrounding the spheres and the 
biomaterials particles (Figures 8F). Moreover, the 
¿nal amount of CHA, observed after 42 days, was 
Figure 6- Representative photomicrographs of alveolar 
socket after 7 days. A and B: Control group; C and D: HA 
??????? ? ??? ?? ??? ?????? ??? ????? ????????????????? ??
??? ???????????????????????????????? ?????????????????????
????????????????????????????????????????????????????????
E, respectively). Pre-existing bone (PEB); Connective 
tissue (CT); Osteoblasts pavement (black arrow); serum 
hemorrhagic exudate (*); Newly formed bone (NFB); 
????????????? ?????????? ????? ???????? ????? ???????????????
(HA); nanostructured carbonated hydroxyapatite/calcium 
alginate (CHA). Hematoxylin and eosin stained.
Figure 5- Multiparametric cytotoxicity assay with human 
osteoblastic cells. Results showed as percentage of 
???????? ?????? ?????????? ????????? ?????????? ?? ?? ???? ????
other groups (p<0.05)
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smaller compared to the amount of HA at the same 
experimental time (Figures 8C and 8E), and in CHA 
group the newly formed bone seems to be in higher 
amount than in HA group (Figures 8D and 8F).
Histomorphometric analysis
BV/TV% (p<0.05)
Histomorphometric analysis showed a signi¿cant 
increase of BV/TV% in CHA group compared with 
HA after 21 and 42 days from surgery. Moreover, 
we found a time dependent increase of BV/TV% in 
CHA group at 42 and 21 days compared with 7-day 
time point and 42 days compared with 21-day 
time point. The HA showed a signi¿cant increase 
at 21-day and 42-day compared with 7-day time 
point, following by a stabilization of bone formation 
at 42 days compared with 21 days. The control 
group presented a signi¿cant increase of BV/TV% 
compared with HA in all experimental groups, 
however, compared with CHA group, the difference 
was observed only at 42 days (p<0.05) (Figure 9A).
BiomatV/TV%
The Figure 9B presents a time-dependent trend 
of reduction in BiomatV/TV% presence in both 
groups after biomaterials implant. A signi¿cant 
decrease in BiomatV/TV% of CHA at 42 days after 
surgery compared with 7 and 21 days was found, 
while HA showed a reduction in biomaterial at 42 
days compared with only 7 days. Also, CHA group 
presented a higher biosorption of BiomatV/TV% 
compared with HA at 42 days. Speci¿cally, CHA 
showed almost 2-fold greater biosorption than HA 
at 42 days (p<0.05).
RANKL/OPG analysis
OPG levels signi¿cantly decreased between 7 
and 42 days in the HA group (p<0.05), whereas no 
signi¿cant effect of time was found for this molecule 
in the CHA group. The RANKL concentration was 
signi¿cantly higher (p<0.05) in the CHA group 
Figure 7- Representative photomicrographs of alveolar 
socket after 21 days. A and B: Control group; C and D: HA 
???????????????????????????????????????????????????????
??? ??? ?? ???? ?? ???? ?????????? ??? ???????? ?????????????
????????????????????????????????????????????????????????
A, C and E, respectively). Pre-existing bone (PEB); 
Connective tissue (CT); Osteoblasts pavement (black 
arrow); hemorrhagic exudate (*); Newly formed bone 
(NFB); hydroxyapatite (HA); nanostructured carbonated 
hydroxyapatite/calcium alginate (CHA). Hematoxylin and 
eosin stained
Figure 8- Representative photomicrographs of alveolar 
socket after 42 days. A and B: Control group; C and D: HA 
???????????????????????????????????????????????????????
??? ??? ?? ???? ?? ???? ?????????? ??? ???????? ?????????????
????????????????????????????????????????????????????????
A, C and E, respectively). Pre-existing bone (PEB); 
Connective tissue (CT); Osteoblasts pavement (black 
arrow); hemorrhagic exudate (*); Newly formed bone 
(NFB); hydroxyapatite (HA); nanostructured carbonated 
hydroxyapatite/calcium alginate (CHA). Hematoxylin and 
eosin stained
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compared to the HA group after 7 days, and 
decreased from 7 to 42 days, whereas it remained 
stable at lower levels for the HA group. The RANKL/
OPG ratio was higher in the CHA group compared 
to the HA group after 7 days, but not after 42 
days. There was no signi¿cant difference in this 
ratio between 7 and 42 days in the CHA group 
(Figure 10).
DISCUSSION
The use of spheres or granules to biocompatible 
materials for clinical use has been previously 
proposed6,21,24, as they may be injectable and 
moldable, and simulate a porous environment 
for increased osteoconductivity. In this context, 
carbonated nanostructured hydroxyapatite/sodium 
alginate spheres may be a promising biomaterial 
for bone replacement. Carbonated hydroxyapatite 
is described as more bioactive and soluble than 
stoichiometric HA, mainly due to properties such 
as its particle size, surface area, and morphology. 
Also, nanostructured CHA with low crystallinity may 
present improved characteristics that are desirable 
in many ¿elds, including tissue engineering and 
dental implantology28. This report presents an in 
vitro and in vivo analysis of the biocompatibility of 
nanostructured carbonated hydroxyapatite/sodium 
alginate as a bone substitute in the alveolar bones 
of rats.
One of the methodological advantages of the 
in vitro model applied in the present work was 
that, within the same group of treated cells, three 
different parameters were evaluated. The relevance 
of this difference becomes evident when we 
consider that the results obtained using only one 
method are often overestimated or underestimated 
due to interference or methodological limitations. 
Previous studies have revealed conÀicts between 
the results obtained with tetrazolium-based assays 
and other parameters3,9. Therefore, while the XTT 
assay showed that neither of the tested materials 
affects cell metabolism, the other assays ensured 
that membrane integrity (NR) and proliferation 
(CVDE assay) were also preserved upon exposure 
to HA and CHA. In fact, there is not a general 
consensus on nanoparticle toxicity (as it is totally 
dependent of the physicochemical nature of the 
material). For instance, literature indicates that the 
toxicity of nanoHA is closely related to particle size8. 
The spheres of the present work are nanostructured 
(i.e., synthesized from nanocrystals, even though 
the ¿nal product is on the micrometric scale). 
Therefore, there was no direct expectancy of 
cytotoxicity. Nevertheless, in order to guarantee 
the absence of signi¿cant adverse effects, three 
different cell viability parameters were successfully 
accessed in vitro, prior to animal testing.
Another important feature of in vitro analyses 
is the choice of the cell type to be exposed to the 
tested material. MC3T3-E1 cells are pre-osteoblasts 
that are able to produce a mineral matrix when 
subjected to the correct stimulus. Because these 
cells are of murine origin, the in vitro test was able 
to reduce the risk of exposure of the rats during 
the in vivo steps of the present work. However, 
our model also included human osteoblasts in 
primary culture. These cells exhibit a greater 
proximity to the end-use of the materials because 
the integrity of their genome is often preserved 
(in contrast to transformed or tumoral cell lines), 
and osteoblasts are among the cell types that are 
Figure 9- The bone volume density (BV/TV%) (A), and biomaterials volume density (BiomatV/TV%) (B) after 7, 21, and 
???????????? ????????????????????????????????????????????????????????????????????????????????????????????????????????????
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Figure 10- Serum concentrations assay of RANKL/
OPG in operated rats after 7 and 42 days. Abbreviations: 
CHA=carbonated hydroxyapatite/sodium alginate; 
??????????????????????????????????????????????????????
???????????????????????????????????????????
intended to interact with the material during new 
bone formation20.
Our in vivo results showed that nanostructured 
CHA and stoichiometric HA grafts are biocompatible 
with bone repair in rats. It was observed through 
histological analysis that CHA group showed 
intense bone formation in 42 days, displaying 
layers of identi¿able osteoblastic cells and large. 
Moderate inÀammatory in¿ltrate was observed in 
both biomaterials groups, especially seven days 
after surgery, although they decreased by the 
42nd day, indicating the absence of an undesirable 
chronic inÀammatory response. The amount of 
identifiable biomaterial also decreased from 7 
to 42 days, mainly in the CHA group, indicating 
greater absorption of the material, probably due 
to a high concentration of phagocytic cells around 
the biomaterial. The greater absorption of CHA 
observed during this study corroborates previous 
studies, showing that CHA exhibits higher solubility 
and absorption due to its lower crystallinity14,15. In 
fact, nanostructured CHA spheres present greater 
in vivo resorption, even when grafted in maxillary 
sinus28. Analysis of histological slides stained with 
HE showed that CHA is also osteoconductive, 
leading to centripetal bone formation (towards the 
center of the defect).
Several proteins may be explored as markers 
of the bone remodeling process, e.g.: bone 
sialoprotein (BSP), osteoclast-speci¿c enzymes, 
such as tartrate-resistant acid phosphatase or 
cathepsin K, type I collagen, osteocalcin, alkaline 
phosphatase, and others. Among those, the ratio 
of the important bone regulatory proteins RANKL 
and OPG represent an important tool for the 
understanding of the osteoclast-mediated resorption 
process of both bone and biomaterials. The RANKL/
OPG system is described as a dominant mediator 
of osteoclastogenesis25. A better understanding 
of this system led to a new perspective regarding 
the molecular biology of osteoclasts and bone 
homeostasis. Speci¿cally, the interaction between 
the osteoblast-secreted protein RANKL and the 
osteoclast receptor RANK is required for osteoclast 
differentiation and proliferation, while OPG acts as 
a soluble receptor and an antagonist to RANKL, 
preventing its binding to and activation of RANK19. 
The results of the present study showed that 
grafting with CHA induced an increase in RANKL 
production within one week, shifting the RANKL/
OPG balance to favor resorption. These ¿ndings 
suggested that resorption of this biomaterial 
occurred in the early days following grafting, which 
was not observed in the HA group. This process 
could be involved in reducing the amount of the 
biomaterial present because osteoclasts release 
acid (H+), as well as other agents that dissolve 
crystals of calcium salts26, and may act to solubilize 
calcium phosphate from the biomaterial, favoring its 
absorption. Other in vivo and in vitro studies have 
shown that CHA (despite not being nanostructured) 
is preferentially resorbed by osteoclasts14,15. 
However, even though there was an increase in the 
number of multinucleated cells observed around 
the biomaterial, other tests must be performed to 
verify their identity as osteoclasts. It is important 
to note that other studies30 have demonstrated an 
increase in the RANK/OPG ratio in rats exposed to 
more-absorbable calcium phosphates, through a 
process that remains to be elucidated but seems 
to be associated with the levels of parathyroid 
hormone. Nevertheless, the present results may 
provide further evidence of increased biosorption 
of nanostructured CHA compared to stoichiometric 
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crystalline HA.
CONCLUSION
Based on these results we can conclude that 
spheres of nanostructured CHA are cytocompatible 
with both murine and human primary bone cells. This 
material presented biocompatibility and improved 
osteoconductive and biosorption properties when 
compared with stoichiometric hydroxyapatite 
regarding the alveolar bone repair in dental sockets. 
The increased resorption and the initial release 
of molecules involved in the activation of bone 
remodeling may indicate desirable properties of 
biomaterials, intended for their use in bone therapy 
and bone replacement following dental trauma prior 
to implantation surgery.
ACKNOWLEDGEMENTS
The authors acknowledge the ¿nancial support 
by the Brazilian agencies FAPERJ – Rio de Janeiro 
Research Foundation, and CNPq – National Council 
of Scienti¿c and Technological Development.
REFERENCES
1- Almasri M, Altalibi M. Ef¿cacy of reconstruction of alveolar 
bone using an alloplastic hydroxyapatite tricalcium phosphate 
graft under biodegradable chambers. Br J Oral Maxillofac Surg. 
2011;49:469-73.
2- Alves Cardoso D, Jansen JA, Leeuwenburgh SC. Synthesis 
and application of nanostructured calcium phosphate ceramics 
for bone regeneration. J Biomed Mater Res B Appl Biomater. 
2012;100:2316-26.
3- Bauer TW. Bone graft substitutes. Skeletal Radiol. 2007;36:1105-
7.
4- Brandt J, Henning S, Michler G, Hein W, Bernstein A, Schulz M. 
Nanocrystalline hydroxyapatite for bone repair: an animal study. 
J Mater Sci Mater Med. 2010;21:283-94.
5- Calasans-Maia M, Calasans-Maia J, Santos S, Mavropoulos 
E, Farina M, Lima I, et al. Short-term in vivo evaluation of zinc-
containing calcium phosphate using a normalized procedure. Mater 
Sci Eng C Mater Biol Appl. 2014;41:309-19.
6- Daculsi G. Biphasic CaP granules concept for injectable and 
mouldable bone substitute. Adv Sci Technol. 2006;49:9-13.
7- De-Deus G, Canabarro A, Alves G, Linhares A, Senne 
MI,  Granjeiro JM. Optimal cytocompatibility of a bioceramic 
nanoparticulate cement in primary human mesenchymal cells. J 
Endod. 2009;35:1387-90.
8- Ding T, Xue Y, Lu H, Huang Z, Sun J. Effect of particle size of 
hydroxyapatite nanoparticles on its biocompatibility. IEEE Trans 
Nanobioscience. 2012;11:336-40.
9- Donnelly E, Chen DX, Boskey AL, Baker SP, van der Meulen 
MC. Contribution of mineral to bone structural behavior and tissue 
mechanical properties. Calcif Tissue Int. 2010;87:450-60.
10- Ginebra MP, Espanol M, Montufar EP, Perez RA, Mestres 
G. New processing approaches in calcium phosphate cements 
and their applications in regenerative medicine. Acta Biomater. 
2010;6:2863-73.
11- Grabowski G, Cornett CA. Bone graft and bone graft substitutes 
in spine surgery: current concepts and controversies. J Am Acad 
Orthop Surg. 2013;21:51-60.
12- Grossardt C, Ewald A, Grover LM, Barralet JE, Gbureck U. 
Passive and active in vitro resorption of calcium and magnesium 
phosphate cements by osteoclastic cells. Tissue Engin A. 
2010;16:3687-95.
13- Hallman M, Mordenfeld A, Strandkvist T. Bone replacement 
following dental trauma prior to implant surgery - present status. 
Dent Traumatol. 2009;25:2-11.
14- Hasegawa S, Neo M, Tamura J, Fujibayashi S, Takemoto M, 
Shikinami Y, et al. In vivo evaluation of a porous hydroxyapatite/
poly-DL-lactide composite for bone tissue engineering. J Biomed 
Mater Res A. 2007;81:930-8.
15- Hasegawa S, Tamura J, Neo M, Goto K, Shikinami Y, Saito 
M, et al. In vivo evaluation of a porous hydroxyapatite/poly-DL-
lactide composite for use as a bone substitute. J Biomed Mater 
Res A. 2005;75:567-79.
16- Hing KA. Bone repair in the twenty-¿rst century: biology, 
chemistry or engineering? Philos Trans A Math Phys Eng Sci. 
2004;362:2821-50.
17- Horváth A, Stavropoulos A, Windisch P, Lukács L, Gera I, 
Sculean A. Histological evaluation of human intrabony periodontal 
defects treated with an unsintered nanocrystalline hydroxyapatite 
paste. Clin Oral Investig. 2013;17:423-30.
18- Kim do K, Lee SJ, Cho TH, Hui P, Kwon MS, Hwang SJ. 
Comparison of a synthetic bone substitute composed of carbonated 
apatite with an anorganic bovine xenograft in particulate forms in 
a canine maxillary augmentation model. Clin Oral Implants Res. 
2010;21:1334-44.
19- Kobayashi Y, Udagawa N, Takahashi N. Action of RANKL 
and OPG for osteoclastogenesis. Crit Rev Eukaryot Gene Expr. 
2009;19:61-72.
20- Lima IR, Alves GG, Soriano CA, Campaneli AP, Gasparoto TH, 
Ramos Junior ES, et al. Understanding the impact of divalent cation 
substitution on hydroxyapatite: an in vitro multiparametric study 
on biocompatibility. J Biomed Mater Res Part A. 2011;98A:351-8.
21- Lomelino RO, Castro-Silva II, Linhares AB, Alves GG, Santos 
SR, Gameiro VS, et al. The association of human primary bone 
cells with biphasic calcium phosphate (ǃTCP/HA 70:30) granules 
increases bone repair. J Mater Sci Mater Med. 2012;23:781-8.
22- Luo ZB, Zhang QB, Zhang ZQ, Chen D, Yan WX, Li KF, 
et al. Performance of coralline hydroxyapatite in sinus Àoor 
augmentation: a retrospective study. Clin Oral Investig. 
2013;17:2003-10.
23- McMahon RE, Wang L, Skoracki R, Mathur AB. Development of 
nanomaterials for bone repair and regeneration. J Biomed Mater 
Res B Appl Biomater. 2013;101:387-97.
24- Mitri F, Alves G, Fernandes G, K|nig B, Rossi AJ, Granjeiro J. 
Cytocompatibility of porous biphasic calcium phosphate granules 
with human mesenchymal cells by a multiparametric assay. Artif 
Organs. 2012;36:535-42.
25- Okamura H, Yang D, Yoshida K, Haneji T. Protein phosphatase 
2a Calpha is involved in osteoclastogenesis by regulating RANKL 
and OPG expression in osteoblasts. FEBS Lett. 2013;587:48-53.
26- Ozdemir T, Higgins AM, Brown JL. Osteoinductive biomaterial 
geometries for bone regenerative engineering. Curr Pharm Des. 
2013;19:3446-55.
27- Rousselle AV, Heymann D. Osteoclastic acidi¿cation pathways 
during bone resorption. Bone. 2002;30:533-40.
28- Sunouchi K, Tsuru K, Maruta M, Kawachi G, Matsuya S, 
Terada Y, et al. Fabrication of solid and hollow carbonate apatite 
microspheres as bone substitutes using calcite microspheres as 
a precursor. Dent Mater J. 2012;31:549-57.
29- Valiense H, Barreto M, Resende RF, Alves AT, Rossi AM, 
Mavropoulos E, et al. In vitro and in vivo evaluation of strontium-
containing nanostructured carbonated hydroxyapatite/sodium 
alginate for sinus lift in rabbits. J Biomed Mater Res Part B Appl 
Biomater. 2015. doi: 10.1002/jbm.b.33392. Epub ahead of print.
30- Yassuda DH, Costa NF, Fernandes GO, Alves GG, Granjeiro 
JM, Soares GDA. Magnesium incorporation into ǃ - TCP reduced 
its in vivo resorption by decreasing parathormone production. J 
Biomed Mat Res A. 2013;101(7):1986-1993.
Cytocompatibility and biocompatibility of nanostructured carbonated hydroxyapatite spheres for bone repair
2015;23(6):599-608
